Sanofi Publishes the P-III (XTEND-Kids) Study Data of Altuviiio to Treat Children with Severe Hemophilia A in the NEJM
Shots:
- Sanofi has published results from the pivotal P-III (XTEND-Kids) trial evaluating Altuviiio (50IU/kg, QW) prophylaxis in treatment-experienced patients (n=74; <12yrs.) with severe hemophilia A for 52wks. in the NEJM
- Study reached its 1EPs & 2EPs, demonstrating zero factor VIII inhibitor development; median annualized bleed rate (ABR) was 0.00 with an estimated mean ABR of 0.61 in 73 patients. 82% of children experienced zero joint bleeds, suggesting Altuviiio’s potential of long-term joint health preservation
- Additionally, an ongoing XTEND-ed extension study is assessing the long-term safety & efficacy of Altuviiio in severe hemophilia A patients (up to 4yrs.)
Ref: Globenewswire | Image: Sanofi
Related News:- Sanofi and Sobi Present P-III Study (XTEND-Kids) Results of Altuviiio for Severe Hemophilia A at ISTH 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
